These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 35858386)

  • 1. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Taha TY; Tabata T; Chen IP; Ott M; Doudna JA
    medRxiv; 2022 Jan; ():. PubMed ID: 34981067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
    Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
    EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
    Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
    J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
    Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants.
    Lusvarghi S; Stauft CB; Vassell R; Williams B; Baha H; Wang W; Neerukonda SN; Wang T; Weiss CD
    PLoS Pathog; 2023 Nov; 19(11):e1011788. PubMed ID: 37943965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
    Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
    Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain.
    Li J; Li X; Mao H; Huang C; Sun Y; Miao L; Li J; Song W; Zhang Y; Huang J; Chen K
    Virus Res; 2023 Jul; 332():199131. PubMed ID: 37178794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity.
    Kuzmina A; Korovin D; Cohen Lass I; Atari N; Ottolenghi A; Hu P; Mandelboim M; Rosental B; Rosenberg E; Diaz-Griffero F; Taube R
    Heliyon; 2023 Jun; 9(6):e16750. PubMed ID: 37292300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.